Crohn's disease

TL;DR: The Brief Symptom Inventory (BSI) as discussed by the authors is a self-report measure of psychological symptoms in clinical and non-clinical populations, but norms for BSI are lacking for patients with chronic illness.

TL;DR: The decision to discontinue therapy must be based on individual approach, taking into account the severity, extension, and duration of the disease, the possibility of side adverse effects, the risk of relapse, and patient’s preferences.

TL;DR: The secretion of VEGF-A and immunosuppression are distinct potency mechanisms of human bone marrow mesenchymal stromal cells.

TL;DR: Atención Primaria (AP) and Gastroenterología (GG) collaborate in the management of patients with inflammatory bowel disease (IBD) and how to address them, with the aim of subsequently developing concrete proposals and projects as mentioned in this paper .

TL;DR: A meta-analysis of Crohn’s disease and ulcerative colitis genome-wide association scans is undertaken, followed by extensive validation of significant findings, with a combined total of more than 75,000 cases and controls.

TL;DR: The results suggest that counterbalancing dysbiosis using F. prausnitzii as a probiotic is a promising strategy in CD treatment and exhibits anti-inflammatory effects on cellular and TNBS colitis models, partly due to secreted metabolites able to block NF-κB activation and IL-8 production.

TL;DR: Differences in incidence across age, time, and geographic region suggest that environmental factors significantly modify the expression of Crohn's disease and ulcerative colitis.

TL;DR: A crucial role is revealed for the autophagy pathway and proteins in immunity and inflammation, and they balance the beneficial and detrimental effects of immunity andinflammation, and thereby may protect against infectious, autoimmune and inflammatory diseases.